|
Name |
Butyrolactone III
|
Molecular Formula | C24H24O8 | |
IUPAC Name* |
methyl 2-[[3-[(3,3-dimethyloxiran-2-yl)methyl]-4-hydroxyphenyl]methyl]-4-hydroxy-3-(4-hydroxyphenyl)-5-oxofuran-2-carboxylate
|
|
SMILES |
CC1(C(O1)CC2=C(C=CC(=C2)CC3(C(=C(C(=O)O3)O)C4=CC=C(C=C4)O)C(=O)OC)O)C
|
|
InChI |
InChI=1S/C24H24O8/c1-23(2)18(31-23)11-15-10-13(4-9-17(15)26)12-24(22(29)30-3)19(20(27)21(28)32-24)14-5-7-16(25)8-6-14/h4-10,18,25-27H,11-12H2,1-3H3
|
|
InChIKey |
FWHAYHIGJSFGKO-UHFFFAOYSA-N
|
|
Synonyms |
Butyrolactone III; MLS000877035; MEGxm0_000070; CHEMBL1461124; ACon0_000894; ACon1_002214; HMS2270H16; 87414-45-7; NCGC00179715-01; SMR000440635; NCGC00179715-03!methyl 2-[[3-[(3,3-dimethyloxiran-2-yl)methyl]-4-hydroxyphenyl]methyl]-4-hydroxy-3-(4-hydroxyphenyl)-5-oxofuran-2-carboxylate
|
|
CAS | 87414-45-7 | |
PubChem CID | 16681743 | |
ChEMBL ID | CHEMBL1461124 |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 440.4 | ALogp: | 3.0 |
HBD: | 3 | HBA: | 8 |
Rotatable Bonds: | 7 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 126.0 | Aromatic Rings: | 4 |
Heavy Atoms: | 32 | QED Weighted: | 0.46 |
Caco-2 Permeability: | -5.108 | MDCK Permeability: | 0.00002250 |
Pgp-inhibitor: | 0.041 | Pgp-substrate: | 0.002 |
Human Intestinal Absorption (HIA): | 0.01 | 20% Bioavailability (F20%): | 0.258 |
30% Bioavailability (F30%): | 0.979 |
Blood-Brain-Barrier Penetration (BBB): | 0.041 | Plasma Protein Binding (PPB): | 96.34% |
Volume Distribution (VD): | 0.335 | Fu: | 3.38% |
CYP1A2-inhibitor: | 0.04 | CYP1A2-substrate: | 0.659 |
CYP2C19-inhibitor: | 0.854 | CYP2C19-substrate: | 0.481 |
CYP2C9-inhibitor: | 0.874 | CYP2C9-substrate: | 0.849 |
CYP2D6-inhibitor: | 0.471 | CYP2D6-substrate: | 0.802 |
CYP3A4-inhibitor: | 0.901 | CYP3A4-substrate: | 0.549 |
Clearance (CL): | 14.09 | Half-life (T1/2): | 0.475 |
hERG Blockers: | 0.023 | Human Hepatotoxicity (H-HT): | 0.194 |
Drug-inuced Liver Injury (DILI): | 0.697 | AMES Toxicity: | 0.224 |
Rat Oral Acute Toxicity: | 0.713 | Maximum Recommended Daily Dose: | 0.613 |
Skin Sensitization: | 0.128 | Carcinogencity: | 0.292 |
Eye Corrosion: | 0.003 | Eye Irritation: | 0.115 |
Respiratory Toxicity: | 0.056 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC002729 | 0.755 | D0J7RK | 0.319 | ||||
ENC000875 | 0.755 | D06KYN | 0.299 | ||||
ENC002552 | 0.740 | D06TJJ | 0.293 | ||||
ENC002711 | 0.725 | D0Q9ON | 0.288 | ||||
ENC002705 | 0.725 | D0Q0PR | 0.288 | ||||
ENC002900 | 0.716 | D04XEG | 0.276 | ||||
ENC003721 | 0.708 | D04AIT | 0.272 | ||||
ENC002561 | 0.680 | D00LFB | 0.270 | ||||
ENC002571 | 0.656 | D0U3YB | 0.267 | ||||
ENC003113 | 0.636 | D0Q1IT | 0.266 |